血清HE4联合CA125检测对妇科良恶性肿瘤的诊断效果

Diagnostic value of serum HE4 combined with CA125 for benign and malignant gynecologic tumors

目的探讨血清人附睾上皮分泌蛋白4（HE4）联合糖类抗原125（CA125）检测对妇科良恶性肿瘤的诊断效果，为妇科良恶性肿瘤临床诊断提供新方向。 方法选取2016年1月至2017年1月于济源市人民医院接受治疗的妇科肿瘤患者128例作为实验组，按疾病性质将其分为良性肿瘤组（子宫肌瘤组）与恶性肿瘤组（子宫内膜癌组、宫颈癌组、卵巢癌组）。另选取60例体检人员作为对照组。观察比较实验组与对照组血清HE4及CA125水平及两者联合检测在恶性妇科肿瘤诊断中的效果。结果对照组与子宫肌瘤组HE4水平及CA125水平比较差异未见统计学意义（P〉0.05）；对照组与子宫内膜癌组、宫颈癌组、卵巢癌组HE4水平及CA125水平比较，差异有统计学意义（P〈0.05）；子宫肌瘤组与子宫内膜癌组、宫颈癌组、卵巢癌组HE4水平及CA125水平比较，差异有统计学意义（P〈0.05）。与血清HE4水平、CA125水平单一指标检测比较，联合检测的阳性率高于单一指标检测（P〈0.05）；三类检测方法对于对照组、良性肿瘤组、恶性肿瘤组的检出阳性率比较，差异有统计学意义（P〈0.05）。HE4水平联合CA125水平指标检测妇科良恶性肿瘤的AUG ROC〉0.5，实验结果具有诊断准确性。结论血清HE4联合CA125对妇科良、恶性肿瘤的诊断效果显著，具有诊断准确性，值得临床推广。

Objective To investigate the diagnostic value of serum human epididymis protein 4 （HE4） combined with carbohydrate antigen （CA125） for gynecologic benign and malignant tumors, which provides a new direction for clinical diagnosis of gynecologic benign and malignant tumors. Methods A total of 128 gynecologic tumor patients treated in Jiyuan People＇s Hospital from January 2016 to January 2017 were selected as experimental group, and were divided into benign tumor group （hysteromyoma group） and malignant tumor group （endometrial cancer group, cervical cancer group and ovarian cancer group） according to tumor nature. Another 60 healthy persons were selected as control group. The levels of serum HE4 and CA125 were observed and compared among groups, and their diag- nostic value of combination of them for malignant gynecologic tumor was analyzed. Results There was no significant difference in HE4 level and CA125 level between control group and hysteromyoma group （P 〉0. 05 ）. There was a significant difference in HE4 level and CA125 level between control group and endometrial cancer group, cervical cancer group and ovarian cancer group （P 〈 0. 05）. There were sig- nificant differences in HE4 level and CA125 level between hysteromyoma group and endometrial carcino- ma group, cervical cancer group and ovarian cancer group （P 〈 0. 05）. Compared with the single index of serum HE4 and CA125, the positive rate of combined detection was higher than that of single index （P 〈 0.05 ）. The positive rates of three kinds of detection methods in control group, benign tumor group and malignant tumor group were statistically significant （P 〈 0.05 ）. The HE4 combined with CA125 lev- el can accurately diagnose benign and malignant gynecologic tumor, of which AUG ROC 〉 0.5. Conclusions Serum HE4 combined with CA125 is effective in the diagnosis of benign and malignant gy-necologic tumors. It has the accuracy in diagnosis and is worthy of clinical promotion.